Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients.

Sannino G, Marchetto A, Ranft A, Jabar S, Zacherl C, Alba-Rubio R, Stein S, Wehweck FS, Kiran MM, Hölting TLB, Musa J, Romero-Pérez L, Cidre-Aranaz F, Knott MML, Li J, Jürgens H, Sastre A, Alonso J, Da Silveira W, Hardiman G, Gerke JS, Orth MF, Hartmann W, Kirchner T, Ohmura S, Dirksen U, Grünewald TGP.

EBioMedicine. 2019 Sep;47:156-162. doi: 10.1016/j.ebiom.2019.08.002. Epub 2019 Aug 16.

2.

Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.

Dallmayer M, Li J, Ohmura S, Alba Rubio R, Baldauf MC, Hölting TLB, Musa J, Knott MML, Stein S, Cidre-Aranaz F, Wehweck FS, Romero-Pérez L, Gerke JS, Orth MF, Marchetto A, Kirchner T, Bach H, Sannino G, Grünewald TGP.

Cell Death Dis. 2019 Feb 11;10(2):116. doi: 10.1038/s41419-019-1372-0.

3.

Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma.

Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TLB, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MML, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TGP.

Int J Cancer. 2019 Feb 15;144(4):859-867. doi: 10.1002/ijc.31903. Epub 2018 Dec 4.

4.

Systematic identification of cancer-specific MHC-binding peptides with RAVEN.

Baldauf MC, Gerke JS, Kirschner A, Blaeschke F, Effenberger M, Schober K, Rubio RA, Kanaseki T, Kiran MM, Dallmayer M, Musa J, Akpolat N, Akatli AN, Rosman FC, Özen Ö, Sugita S, Hasegawa T, Sugimura H, Baumhoer D, Knott MML, Sannino G, Marchetto A, Li J, Busch DH, Feuchtinger T, Ohmura S, Orth MF, Thiel U, Kirchner T, Grünewald TGP.

Oncoimmunology. 2018 Jul 23;7(9):e1481558. doi: 10.1080/2162402X.2018.1481558. eCollection 2018.

5.

Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility.

Machiela MJ, Grünewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, Zaidi S, Grossetete-Lalami S, Ballet S, Lapouble E, Laurence V, Michon J, Pierron G, Kovar H, Gaspar N, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, Corradini N, Bérard PM, Freedman ND, Rothman N, Dagnall CL, Burdett L, Jones K, Manning M, Wyatt K, Zhou W, Yeager M, Cox DG, Hoover RN, Khan J, Armstrong GT, Leisenring WM, Bhatia S, Robison LL, Kulozik AE, Kriebel J, Meitinger T, Metzler M, Hartmann W, Strauch K, Kirchner T, Dirksen U, Morton LM, Mirabello L, Tucker MA, Tirode F, Chanock SJ, Delattre O.

Nat Commun. 2018 Aug 9;9(1):3184. doi: 10.1038/s41467-018-05537-2.

6.

Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets.

Baldauf MC, Orth MF, Dallmayer M, Marchetto A, Gerke JS, Rubio RA, Kiran MM, Musa J, Knott MML, Ohmura S, Li J, Akpolat N, Akatli AN, Özen Ö, Dirksen U, Hartmann W, de Alava E, Baumhoer D, Sannino G, Kirchner T, Grünewald TGP.

Oncotarget. 2017 Aug 4;9(2):1587-1601. doi: 10.18632/oncotarget.20098. eCollection 2018 Jan 5.

7.

Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.

Thiel U, Schober SJ, Einspieler I, Kirschner A, Thiede M, Schirmer D, Gall K, Blaeschke F, Schmidt O, Jabar S, Ranft A, Alba Rubío R, Dirksen U, Grunewald TGP, Sorensen PH, Richter GHS, von Lüttichau IT, Busch DH, Burdach SEG.

Oncoimmunology. 2017 Apr 12;6(5):e1312239. doi: 10.1080/2162402X.2017.1312239. eCollection 2017.

8.

Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.

Kirschner A, Thiede M, Grünewald TG, Alba Rubio R, Richter GH, Kirchner T, Busch DH, Burdach S, Thiel U.

Oncoimmunology. 2017 Jan 17;6(2):e1273301. doi: 10.1080/2162402X.2016.1273301. eCollection 2017.

9.

Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Schirmer D, Grünewald TG, Klar R, Schmidt O, Wohlleber D, Rubío RA, Uckert W, Thiel U, Bohne F, Busch DH, Krackhardt AM, Burdach S, Richter GH.

Oncoimmunology. 2016 Apr 25;5(6):e1175795. doi: 10.1080/2162402X.2016.1175795. eCollection 2016 Jun.

10.

Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.

Blaeschke F, Thiel U, Kirschner A, Thiede M, Rubio RA, Schirmer D, Kirchner T, Richter GHS, Mall S, Klar R, Riddell S, Busch DH, Krackhardt A, Grunewald TG, Burdach S.

Oncotarget. 2016 Jul 12;7(28):43267-43280. doi: 10.18632/oncotarget.9218.

Supplemental Content

Loading ...
Support Center